Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Eli Lilly (NYSE: LLY) has a strong pipeline of new medicines that could increase the stock price. *Stock prices used were the afternoon prices of May 15, 2025. The video was published on May 17, 2025.

Eli Lilly (NYSE: LLY) is gaining market share in a lucrative market that could be a catalyst for a stock price increase.

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Eli Lilly saw a 26% spike in call option activity, hinting that investors are feeling unusually optimistic—or just love drama ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. | Under a mutual agreement with ...